Chimerix Inc. (Nasdaq: CMRX) reported disappointing results from a Phase 3 Suppress trial of brincidofovir in patients undergoing hematopoietic cell transplantation sending the stock price plummeting $28.93 to $6.64.
Disappointing study results for Chimerix
December 28, 2015 at 13:52 PM EST
